Ypsomed
Mayank Chaubey, PhD., MBA, currently serves as Associate Director BDM Drug Delivery Systems at Ypsomed AG and as Director of Business Development for Europe, UK, and APAC at InSphero, where significant contributions include the execution of 3D cell-based pre-clinical projects in oncology, hepatology, and diabetes. With a robust background in business development and strategic consulting, Mayank has held key roles at Solvias and Randstad Switzerland, focusing on B2B partnerships, sales, and client acquisition in the life sciences sector. Mayank's academic credentials include a PhD in Molecular Life Sciences from ETH Zürich, an MBA in Biotechnology from Macquarie University, and executive education in Strategy Execution from Harvard Business School.
This person is not in any teams
This person is not in any offices
Ypsomed
4 followers
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.